)

Teva Pharmaceutical Industries (TEVA) investor relations material
Teva Pharmaceutical Industries Study Update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Study design and context
Ongoing phase IIa trial of atabinib plus modified gemcitabine and nab-paclitaxel in first-line pancreatic cancer patients, with a data cutoff of August 26, 2025.
34 patients enrolled, median age 69, with a significant proportion having liver metastases.
Study population is older than those in pivotal studies for standard of care, with similar distribution of metastases.
No genetic testing required for enrollment, allowing for a broad patient population.
Study funded through 2029 following a $175M underwritten offering and $25M private placement, including strategic investment from Sanofi.
Efficacy results
Six-month overall survival (OS) was 94%, and nine-month OS was 86%, nearly double the benchmark for standard of care.
Median overall survival not yet reached due to a flat survival curve.
Progression-free survival (PFS) at six months was 70%, and at nine months was 53%, with a median PFS of 9.6 months.
Strong separation in OS and PFS compared to all three standard of care regimens, including gemcitabine+nab-paclitaxel, FOLFIRINOX, and NALIRIFOX.
Subgroup analysis showed identical PFS for patients with liver metastases as the overall population.
Robustness and supporting endpoints
Results supported by 95% confidence intervals, with even the lower bound showing significant separation from standard of care.
Surrogate endpoints (overall response rate 39%, disease control rate 81%) also favor atabinib over benchmarks.
Waterfall and spider plots show most patients have shrinking lesions, with slow, durable responses.
Lower rate of censoring than typical for oncology studies, further supporting data robustness.
Efficacy observed in both older and younger, higher fitness patients, and in those with liver metastases.
Next Teva Pharmaceutical Industries earnings date

Next Teva Pharmaceutical Industries earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage